Experience of treating patients with mixed hypertriglyceridemia in a lipid center (clinical case)

Lipid metabolism disorders remain a significant medical and social problem associated with mortality, disability, morbidity and pathologies of the circulatory system. According to international and Russian epidemiological studies, hypertriglyceridemia is a common risk factor for coronary heart disease. Isolated use of non-pharmacological therapy and statin monotherapy is not effective enough, and therefore it is necessary to propagate the experience of combined treatment, supported by modern recommendations. This work shows the possibilities of effective use of combined therapy of lipid metabolism disorders (statin, ezetimibe, alirocumab, fenofibrate) in patients with mixed hypertriglyceridemia.

1. Boytsov S., Katapano A., Barbarash O., Yezhov M., Meshkov A., Voevoda M., Gurevich V., Kashtalap V., Duplyakov D., Vezikova N., Sadykova D. Actual issues of lipid centers’ operation in Russian Federation. Cardiovascular Therapy and Prevention. 2021; 20 (1): 2759. (In Russian) doi:10.15829/1728-8800-2021-2759

2. Meshkov A.N., Ershova A.I., Deev A.D., Metelskaya V.A., Zhernakova Yu.V., Rotar O.P., Shalnova S.A., Boytsov S.A. Distribution of lipid profile values in economically active men and women in Russian federation: results of the ESSE-RF study for the years 2012-2014. Cardiovascular Therapy and Prevention. 2017; 16 (4): 62-67. (In Russian) doi:10.15829/1728-8800-2017-4-62-67

3. Yusuf S., Hawken S., Ounpuu S. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study) case-control study. Lancet. 2004; (364): 937-952. doi:10.1016/S0140-6736(04)17018-9.

4. Pogosova N.V., Oganov R.G., Boytsov S.A., Ausheva A.K., Sokolova O.Yu., Kursakov A.A., Osipova I.V., Antropova O.N., Pozdnyakov Yu.M., Salbieva A.O., Lelchuk I.N., Gusarova T.A., Gomyranova N.V., Skazin N.A., Kotseva K. Secondary prevention in patients with coronary artery disease in Russia and Europe: results from the Russian part of the EUROASPIRE V survey. Cardiovascular Therapy and Prevention. 2020; 19 (6): 2739 (In Russian) doi:10.15829/1728-8800-2020-2739

5. Yezhov M.V., Sergienko I.V., Aronov D.M., Arabidze G.G., Akhmedzhanov N.M., Bazhan S.S., Balakhonova T.V., Barbarash O.L., Boytsov S.A., Bubnova M.G., Voevoda M.I., Galyavich A.S., Gornyakova N.B., Gurevich V.S., Drapkina O.M., Duplyakov D.V., Yeregin S.Ya., Zubareva M.Yu., Karpov R.S., Karpov Yu.Aet al. Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis, Atherosclerosis and Dyslipidemia. 2017; 3: 5-22 (In Russian)

6. Catapano A.L., Graham I., De Backer G., Wiklund O., Chapman M.J., Drexel H., Hoes A.W., Jennings C.S., Landmesser U., Pedersen T.R., Reiner Ž., Riccardi G., Taskinen M.R., Tokgozoglu L., Verschuren W.M.M., Vlachopoulos C., Wood D.A., Zamorano J.L., Cooney M.T.; ESC Scientific Document Group.2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016; 37 (39): 2999-3058. doi:10.1093/eurheartj/ehw272.18.

7. Barbarash O.L., Fedorova N.V., Sedykh D.Yu., Gruzdeva O.V., Khryachkova O.N., Kashtalap V.V., Filimonova A.A. PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders. Russian Journal of Cardiology. 2020; 25 (8): 4010. (In Russian) doi:10.15829/1560-4071-2020-4010

8. Karpov Y., Khomitskaya Y. PROMETHEUS: an observational, cross-sectional, retrospective study of hypertriglyceridemia in Russia. Cardiovasc Diabetol. 2015; 14: 115. doi:10.1186/s12933-015-0268-2.

9. Tsygankova O.V., Ozhiganova N.V., Kashtalap V.V., Bayramova S.S., Latyntseva L.D. Hypertriglyceridemia as a multidisciplinary problem of modern medicine. Complex Issues of Cardiovascular Diseases. 2020; 9 (4): 114-123. (In Russian) doi:10.17802/2306-1278-2020-9-4-114-123

10. Arutyunov G.P., Boytsov S.A., Voyevoda M.I., Gurevich V.S., Drapkina O.M., Kukharchuk V.V., Martynov A.I., Sergiyenko I.V.et al. Correction of Hypertriglyceridemia as the Way to Reduce Residual Risk in Diseases Caused by Atherosclerosis. Conclusion of the Advisory Board of the Russian Society of Cardiology, the Russian Scientific Medical Society of Therapists, the Eurasian Association of Therapists, the Russian National Atherosclerosis Society, the Russian Association of Endocrinologists, and the National League of Cardiologic Genetics. Rational Pharmacotherapy in Cardiology. 2019; 15 (2): 282-288. (In Russian) doi:10.20996/1819-6446-2019-15-2-282-288